Grace Therapeutics, Inc. Accretion Expense
Grace Therapeutics, Inc. (GRCE) reported Accretion Expense of $145.00 thousand for the 12-month period ending 2020-03-31, per its 10-K filed 2021-06-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2021-06-22
- Grace Therapeutics, Inc. accretion expense for the quarter ending 2020-03-31 was $39.00K.
- Grace Therapeutics, Inc. accretion expense for the quarter ending 2019-12-31 was $30.00K.
- Grace Therapeutics, Inc. accretion expense for the quarter ending 2019-09-30 was $40.00K.
- Grace Therapeutics, Inc. accretion expense for the quarter ending 2019-06-30 was $37.00K.
- Grace Therapeutics, Inc. accretion expense for fiscal 2020 was $145.00K, a 7.05% decline from fiscal 2019.
- Grace Therapeutics, Inc. accretion expense for fiscal 2019 was $156.00K.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2020-03-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-22 | $69.00K derived: sum of 2 quarters · filed 2021-06-22 | $109.00K derived: sum of 3 quarters · filed 2021-06-22 | $145.00K 10-K · filed 2021-06-22 |
| 2019-12-31 | $30.00K 10-Q · filed 2021-02-09 | $70.00K derived: sum of 2 quarters · filed 2021-02-09 | $106.00K 10-Q · filed 2021-02-09 | |
| 2019-09-30 | $40.00K 10-Q · filed 2020-11-16 | $77.00K 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | $37.00K 10-Q · filed 2020-08-13 | |||
| 2019-03-31 | $156.00K 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |